Who wants second-line, palliative chemotherapy?

Area of Science:

• Oncology
• Palliative Care
• Health Psychology

Background:

• Second-line palliative chemotherapy is a crucial treatment option for advanced cancer.
• Understanding patient and public perceptions of chemotherapy's value is essential for informed decision-making.
• Previous research has not fully explored the discrepancy between patient acceptance and perceived value by others.

Purpose of the Study:

• To measure the value patients with advanced cancer place on second-line palliative chemotherapy.
• To compare patient-valued chemotherapy benefits with assumptions made by healthy individuals.
• To identify reasons behind treatment acceptance or decline in advanced cancer patients.

Main Methods:

• A questionnaire-based study involving patients with advanced cancer and healthy controls.
• Inclusion of various healthcare professionals (medical oncologists, palliative care physicians, nurses, GPs) as comparison groups.
• Presentation of hypothetical treatment scenarios to assess minimum acceptable chance and duration of benefit.

Main Results:

• Patients with advanced cancer accepted chemotherapy with a lower minimum chance of benefit compared to all other study groups.
• While duration of benefit showed more variation, patients accepting lower time values were more prevalent.
• These findings remained consistent even when hypothetical treatments involved higher toxicity.

Conclusions:

• Individuals with advanced cancer demonstrate a greater willingness to accept second-line chemotherapy with lower chances and shorter durations of benefit than commonly assumed.
• Healthcare professionals should acknowledge and respect these patient preferences when discussing palliative chemotherapy options.
• Recognizing patient-specific value perceptions can improve communication and shared decision-making in advanced cancer care.